Acute myocardial infarction （AMI） is an acute cardiovascular emergency. This study was undertaken to assess the effect of tumor necrosis factor-a （TNF-a） on ventricular arrhythmias induced byAMI in rats in vivo. ...Acute myocardial infarction （AMI） is an acute cardiovascular emergency. This study was undertaken to assess the effect of tumor necrosis factor-a （TNF-a） on ventricular arrhythmias induced byAMI in rats in vivo. Two hundred and forty male Wistar rats were randomized into a sham- operation group, an AMI group, and a recombinant human tumor necrosis factor receptor：Fc fusion protein（rhTNFR：Fc） group. Acute anterior wall myocardial infarction was produced in the AMI group by ligating the left anterior descending coronary artery （LAD）, and there was no ligation but operation in the sham-operation group. The rhTNFR：Fc group was treated with rhTNFR：Fc（10 mg/kg）, a TNF-a antagonist, 24 hours before LAD ligation. The spontaneous and induced programmed electrical stimulation ventricular arrhythmias were recorded at baseline and 10 minutes, 20 minutes, 30 minutes, 60 minutes, 3 hours, 6 hours and 12 hours after ligation. At the same time the protein and mRNA expression levels of TNF-a among different groups were detected by histochemistry and real-time fluorescent quantitative PCR. Expression of TNF-a increased markedly from 10 minutes after infarction, peaked at 20-30 minutes, and returned to baseline gradually in the AMI group and rhTNFR：Fc group. The time- windows of spontaneous and induced ventricular arrhythmias were similar. Compared with the AMI group, the rhTNFR：Fc group showed a lesser expression of TNF-a protein and a lower incidence of ventricular arrhythmias （P〈0.05）. There was no obvious change in the sham-operation group. The expression of TNF-a induced by AMI could contribute to the onset of ventricular arrhythmias.展开更多
目的探讨重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(recombinant human tumor necrosis factor-α receptorⅡ:IgG Fc fusion protein for injection,rhTNFR:Fc)联合甲氨蝶呤(methotrexate,MTX)短期治疗银屑病关节炎(psoriaticarthritis...目的探讨重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(recombinant human tumor necrosis factor-α receptorⅡ:IgG Fc fusion protein for injection,rhTNFR:Fc)联合甲氨蝶呤(methotrexate,MTX)短期治疗银屑病关节炎(psoriaticarthritis,PsA)的疗效与安全性。方法对入院前传统治疗方案(非甾体类消炎药联合甲氨蝶呤或其他免疫抑制剂)治疗3个月以上疗效欠佳的15例患者,入院后给予重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(益赛普,etanercept)25mg,2次/周,皮下注射,同时给予甲氨蝶呤7.5～15mg,1次/周,12周后停用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白,观察患者治疗前后的临床症状、炎性实验室指标的改善情况及药物安全性。结果15例患者关节压痛数、关节肿胀数、银屑病面积和严重度指数(psoriasis area and severity index,PASI)均明显降低,同时血沉及C反应蛋白亦明显下降,且与治疗前相比差异具有统计学意义。1例患者出现注射部位皮肤片状红肿及瘙痒,未予特殊处理后消失,其余患者均未出现明显不良反应。结论重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合甲氨蝶呤短期治疗银屑病关节炎有效、安全、可行。展开更多
目的:探究重组人Ⅱ型肿瘤坏死因子(TNF)受体-抗体融合蛋白联合风湿骨痛片对类风湿性关节炎(RA)患者的疗效。方法:将90例RA患者随机分为观察组和对照组,每组各45例。对照组给予注射重组人Ⅱ型TNF受体-抗体融合蛋白;观察组注射重组人Ⅱ型...目的:探究重组人Ⅱ型肿瘤坏死因子(TNF)受体-抗体融合蛋白联合风湿骨痛片对类风湿性关节炎(RA)患者的疗效。方法:将90例RA患者随机分为观察组和对照组,每组各45例。对照组给予注射重组人Ⅱ型TNF受体-抗体融合蛋白;观察组注射重组人Ⅱ型TNF受体-抗体融合蛋白联合口服风湿骨痛片。比较两组患者的血清炎症因子、炎性指标、临床疗效、美国健康评估问卷(HAQ)、RA28处关节疾病活动度评分(DAS28)。结果:治疗后,两组患者的IL-6、TNF-α水平比治疗前低,IL-10比治疗前高( P <0.05),观察组的IL-6、TNF-α水平低于对照组,IL-10水平高于对照组( P <0.05);两组患者的类风湿因子(RF)、红细胞沉降率(ESR)、C反应蛋白(CRP)炎性指标均较治疗前更低( P<0.05),且观察组低于对照组(P <0.05);观察组患者临床疗效总有效率为93.33%,高于对照组的73.33%( P <0.05);两组患者HAQ 评分、DAS28及症状积分较治疗前更低( P <0.05),且观察组患者HAQ 评分、DAS28 评分及症状积分低于对照组( P <0.05)。结论:对RA患者采用注射重组人Ⅱ型TNF受体-抗体融合蛋白联合口服风湿骨痛片治疗,提高了临床治疗效果和患者生活质量,减轻了患者的痛苦。展开更多
NanoUPLC-ESI MS/MS was used to characterize the primary structure of recombinant human necrosis factor-αreceptorⅡ:IgG Fc fusion protein.The result indicated that the IgG Fc was IgG1 Fc but not others.This study is i...NanoUPLC-ESI MS/MS was used to characterize the primary structure of recombinant human necrosis factor-αreceptorⅡ:IgG Fc fusion protein.The result indicated that the IgG Fc was IgG1 Fc but not others.This study is important for this recombinant protein medicine to enter into international market.展开更多
文摘Acute myocardial infarction （AMI） is an acute cardiovascular emergency. This study was undertaken to assess the effect of tumor necrosis factor-a （TNF-a） on ventricular arrhythmias induced byAMI in rats in vivo. Two hundred and forty male Wistar rats were randomized into a sham- operation group, an AMI group, and a recombinant human tumor necrosis factor receptor：Fc fusion protein（rhTNFR：Fc） group. Acute anterior wall myocardial infarction was produced in the AMI group by ligating the left anterior descending coronary artery （LAD）, and there was no ligation but operation in the sham-operation group. The rhTNFR：Fc group was treated with rhTNFR：Fc（10 mg/kg）, a TNF-a antagonist, 24 hours before LAD ligation. The spontaneous and induced programmed electrical stimulation ventricular arrhythmias were recorded at baseline and 10 minutes, 20 minutes, 30 minutes, 60 minutes, 3 hours, 6 hours and 12 hours after ligation. At the same time the protein and mRNA expression levels of TNF-a among different groups were detected by histochemistry and real-time fluorescent quantitative PCR. Expression of TNF-a increased markedly from 10 minutes after infarction, peaked at 20-30 minutes, and returned to baseline gradually in the AMI group and rhTNFR：Fc group. The time- windows of spontaneous and induced ventricular arrhythmias were similar. Compared with the AMI group, the rhTNFR：Fc group showed a lesser expression of TNF-a protein and a lower incidence of ventricular arrhythmias （P〈0.05）. There was no obvious change in the sham-operation group. The expression of TNF-a induced by AMI could contribute to the onset of ventricular arrhythmias.
文摘目的探讨重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(recombinant human tumor necrosis factor-α receptorⅡ:IgG Fc fusion protein for injection,rhTNFR:Fc)联合甲氨蝶呤(methotrexate,MTX)短期治疗银屑病关节炎(psoriaticarthritis,PsA)的疗效与安全性。方法对入院前传统治疗方案(非甾体类消炎药联合甲氨蝶呤或其他免疫抑制剂)治疗3个月以上疗效欠佳的15例患者,入院后给予重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(益赛普,etanercept)25mg,2次/周,皮下注射,同时给予甲氨蝶呤7.5～15mg,1次/周,12周后停用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白,观察患者治疗前后的临床症状、炎性实验室指标的改善情况及药物安全性。结果15例患者关节压痛数、关节肿胀数、银屑病面积和严重度指数(psoriasis area and severity index,PASI)均明显降低,同时血沉及C反应蛋白亦明显下降,且与治疗前相比差异具有统计学意义。1例患者出现注射部位皮肤片状红肿及瘙痒,未予特殊处理后消失,其余患者均未出现明显不良反应。结论重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合甲氨蝶呤短期治疗银屑病关节炎有效、安全、可行。
文摘目的:探究重组人Ⅱ型肿瘤坏死因子(TNF)受体-抗体融合蛋白联合风湿骨痛片对类风湿性关节炎(RA)患者的疗效。方法:将90例RA患者随机分为观察组和对照组,每组各45例。对照组给予注射重组人Ⅱ型TNF受体-抗体融合蛋白;观察组注射重组人Ⅱ型TNF受体-抗体融合蛋白联合口服风湿骨痛片。比较两组患者的血清炎症因子、炎性指标、临床疗效、美国健康评估问卷(HAQ)、RA28处关节疾病活动度评分(DAS28)。结果:治疗后,两组患者的IL-6、TNF-α水平比治疗前低,IL-10比治疗前高( P <0.05),观察组的IL-6、TNF-α水平低于对照组,IL-10水平高于对照组( P <0.05);两组患者的类风湿因子(RF)、红细胞沉降率(ESR)、C反应蛋白(CRP)炎性指标均较治疗前更低( P<0.05),且观察组低于对照组(P <0.05);观察组患者临床疗效总有效率为93.33%,高于对照组的73.33%( P <0.05);两组患者HAQ 评分、DAS28及症状积分较治疗前更低( P <0.05),且观察组患者HAQ 评分、DAS28 评分及症状积分低于对照组( P <0.05)。结论:对RA患者采用注射重组人Ⅱ型TNF受体-抗体融合蛋白联合口服风湿骨痛片治疗,提高了临床治疗效果和患者生活质量,减轻了患者的痛苦。
文摘NanoUPLC-ESI MS/MS was used to characterize the primary structure of recombinant human necrosis factor-αreceptorⅡ:IgG Fc fusion protein.The result indicated that the IgG Fc was IgG1 Fc but not others.This study is important for this recombinant protein medicine to enter into international market.
